{"id":"intramuscular-vaccine-covaxin","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain/tenderness"},{"rate":"10-20","effect":"Fever"},{"rate":"10-15","effect":"Fatigue"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Myalgia"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"COVAXIN contains inactivated (killed) whole SARS-CoV-2 virus particles combined with an adjuvant (Alum and TLR 7/8 agonist) to enhance immunogenicity. Upon intramuscular injection, the vaccine triggers both humoral (antibody) and cellular (T-cell) immune responses against multiple viral epitopes, providing protection against COVID-19 infection and severe disease.","oneSentence":"COVAXIN is an inactivated whole-virus COVID-19 vaccine that stimulates immune responses against SARS-CoV-2 through presentation of viral antigens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:41.008Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT05258669","phase":"PHASE2, PHASE3","title":"Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults","status":"UNKNOWN","sponsor":"Ocugen","startDate":"2022-02-20","conditions":"COVID-19","enrollment":400},{"nctId":"NCT05639998","phase":"PHASE2","title":"BBV152/BBV154 Heterologus Prime-Boost Study","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2021-09-01","conditions":"Corona Virus Infection","enrollment":608},{"nctId":"NCT05567471","phase":"PHASE3","title":"Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2022-02-26","conditions":"COVID-19 Respiratory Infection","enrollment":875},{"nctId":"NCT05522335","phase":"PHASE3","title":"Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers","status":"UNKNOWN","sponsor":"Bharat Biotech International Limited","startDate":"2022-04-16","conditions":"COVID-19 Respiratory Infection","enrollment":3160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intramuscular vaccine COVAXIN","genericName":"Intramuscular vaccine COVAXIN","companyName":"Bharat Biotech International Limited","companyId":"bharat-biotech-international-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"COVAXIN is an inactivated whole-virus COVID-19 vaccine that stimulates immune responses against SARS-CoV-2 through presentation of viral antigens. Used for COVID-19 prevention in adults and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}